Conivaptan Hydrochloride Injection
Category: Cardiovascular
FDA status: Current · Last FDA update: Sep 16, 2026 · First posted: Mar 14, 2022 (in shortage 4 years 6 months) · 1 manufacturers, 1 listed presentations
As of Sep 16, 2026, the FDA lists Conivaptan Hydrochloride Injection as currently in shortage. Of 1 manufacturer presentations, 1 Unavailable.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) NDC 66220-160-10 |
Cumberland Pharmaceuticals Inc. | Unavailable | Estimated recovery: TBD |
Related medications in shortage
Other Cardiovascular medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Conivaptan Hydrochloride Injection (FDA data as of Sep 16, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Conivaptan Hydrochloride Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/conivaptan-hydrochloride-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).